BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 31079800)

  • 1. Adoptive T-Cell Therapy for Solid Malignancies.
    Jafferji MS; Yang JC
    Surg Oncol Clin N Am; 2019 Jul; 28(3):465-479. PubMed ID: 31079800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead.
    Kirtane K; Elmariah H; Chung CH; Abate-Daga D
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive CD8
    Jiang X; Xu J; Liu M; Xing H; Wang Z; Huang L; Mellor AL; Wang W; Wu S
    Cancer Lett; 2019 Oct; 462():23-32. PubMed ID: 31356845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
    Houot R; Schultz LM; Marabelle A; Kohrt H
    Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive T-Cell Therapy for Cancer.
    Yang JC; Rosenberg SA
    Adv Immunol; 2016; 130():279-94. PubMed ID: 26923004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
    Ott PA; Dotti G; Yee C; Goff SL
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive Cell Therapy for Metastatic Melanoma.
    Merhavi-Shoham E; Itzhaki O; Markel G; Schachter J; Besser MJ
    Cancer J; 2017; 23(1):48-53. PubMed ID: 28114254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.
    Feldman SA; Assadipour Y; Kriley I; Goff SL; Rosenberg SA
    Semin Oncol; 2015 Aug; 42(4):626-39. PubMed ID: 26320066
    [No Abstract]   [Full Text] [Related]  

  • 11. Adoptive immunotherapy for cancer.
    Ruella M; Kalos M
    Immunol Rev; 2014 Jan; 257(1):14-38. PubMed ID: 24329787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive Cell Therapy in Treating Pediatric Solid Tumors.
    Tesfaye M; Savoldo B
    Curr Oncol Rep; 2018 Aug; 20(9):73. PubMed ID: 30069644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting cytokines in adoptive T-cell therapy of cancer.
    Petrozziello E; Sturmheit T; Mondino A
    Immunotherapy; 2015; 7(5):573-84. PubMed ID: 26065481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Driving CARs on the Highway to Solid Cancer: Some Considerations on the Adoptive Therapy with CAR T Cells.
    Abken H
    Hum Gene Ther; 2017 Nov; 28(11):1047-1060. PubMed ID: 28810803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell receptor and chimeric antigen receptor in solid cancers: current landscape, preclinical data and insight into future developments.
    Azizi AA; Pillai M; Thistlethwaite FC
    Curr Opin Oncol; 2019 Sep; 31(5):430-438. PubMed ID: 31335828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive T-cell therapy for cancer: The era of engineered T cells.
    Bonini C; Mondino A
    Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
    Jindal V; Arora E; Gupta S
    Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.
    Srivastava S; Riddell SR
    J Immunol; 2018 Jan; 200(2):459-468. PubMed ID: 29311388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immune cell therapy using iPS cells].
    Yano H; Kaneko S
    Rinsho Ketsueki; 2018; 59(2):225-231. PubMed ID: 29515078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.
    Knochelmann HM; Smith AS; Dwyer CJ; Wyatt MM; Mehrotra S; Paulos CM
    Front Immunol; 2018; 9():1740. PubMed ID: 30140266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.